| References: |
JZL 195 is a potent inhibitor of both FAAH and MAGL (IC50 = 2 and 4 nM, respectively).It poorly inhibits neuropathy target esterase and ABHD6 and does not inhibit other brain serine hydrolases. JZL 195 displays time-dependent inhibition of FAAH and MAGL in vivo, consistent with a covalent mechanism of activation.The in vivo inhibitory actions of JZL 195 against FAAH and MAGL are comparable to those of the selective inhibitors PF-3845 and JZL 184, respectively.Through its inhibitory actions, JZL 195 simultaneously augments brain levels of AEA and 2-AG, producing antinociceptive, cataleptic, and hypomotility effects like those produced by direct CB1 agonists. For the detailed information of JZL-195, the solubility of JZL-195 in water, the solubility of JZL-195 in DMSO, the solubility of JZL-195 in PBS buffer, the animal experiment (test) of JZL-195, the cell expriment (test) of JZL-195, the in vivo, in vitro and clinical trial test of JZL-195, the EC50, IC50,and affinity,of JZL-195, For the detailed information of JZL-195, the solubility of JZL-195 in water, the solubility of JZL-195 in DMSO, the solubility of JZL-195 in PBS buffer, the animal experiment (test) of JZL-195, the cell expriment (test) of JZL-195, the in vivo, in vitro and clinical trial test of JZL-195, the EC50, IC50,and affinity,of JZL-195, Please contact DC Chemicals. |
